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MALDI-IMSThe identiﬁcation of amyloid-binding compounds is a crucial step in the development of imaging probes and
therapeutics for the detection and cure of Alzheimer's disease. Unfortunately, the process typically lags dur-
ing the translation from in vitro to in vivo studies due to the impenetrable nature of the blood brain barrier
(BBB). Here, we integrate ﬂuorescence assay with MALDI imaging mass spectrometry to screen known com-
pounds and repurpose their properties to enable the second function of binding to amyloid plaques. Through
this approach, we identiﬁed an antihistamine compound, promethazine, that can bind to amyloid plaques.
Finally, we demonstrate that promethazine is retained in the amyloid-burdened brain compared to a normal
brain and that its distribution within the brain corroborates with that of amyloid plaques.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Alzheimer's disease (AD) is an age-dependent neurodegenerative dis-
order characterized by a progressive loss of cognitive functionwith initial
deﬁcits in short-term memory and episodic memory losses followed by
increasingly global losses in cognitive function and ultimately death
(Artero and Ritchie, 2003). Today, AD represents 50–70% of the cases of
senile dementia and remains the only top ten cause of death in the United
States without a treatment which directly targets the underlying disease
pathophysiology (Aisen, 2008; Terry and Katzman, 1983). To place
these statistics in perspective, more than 5 million Americans suffer
from this disease, while more than 35 million people are afﬂicted world-
wide (Prince et al., 2011). As a consequence of the baby-boom generation
reaching AD's age of onset in congruence with the demographic aging inashville, TN 37027-2300, USA.
. Pham).
nc. Open access under CC BY-NC-ND lideveloping nations worldwide, the future of AD is becoming increasingly
daunting with its prevalence projected to reach 65.7 million people by
2030 (Association, 2012). In view of the growing socioeconomic catastro-
phe and worldwide health problems associated with AD, the impetus to
develop new diagnostic and treatment strategies for AD has never been
greater.
Currently, in accordance with the amyloid cascade hypothesis of AD
pathogenesis, multiple lines of convergent evidence implicate amyloid-
β (Aβ) plaques as themajor cytopathologic hallmark of AD (Glenner and
Wong, 2012; Hardy and Higgins, 1992; Masters et al., 1985a; Selkoe,
1991a,b). The amyloid cascade hypothesis holds that perturbations in
Aβ peptide formation and clearance result in a clustering of Aβ peptides
to form Aβ plaques, which subsequently cause neuronal death attribut-
able to direct and indirect neurotoxic insults (Lewis et al., 2001;
Markesbery, 1999; Meda et al., 1995; Sheng et al., 1997). At present,
the diagnosis of AD is assigned clinically by assessing a patient's
late-stage cognitive abilities in the context of age, family history and
other risk factors (Hintersteiner et al., 2005; Hort et al., 2010; Sorbi et
al., 2012). However, due to the phenotypic homogeneity of neurological
disorders included in the differential diagnosis of cognitive impairment
as well as atypical presentations both intrinsic to AD and secondary tocense.
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causes of dementia remains a bottleneck with respect to both clinical
therapeutics and basic research (Albert et al., 2011; Artero et al., 2003;
Hardy and Selkoe, 2002; Landau et al., 2011, 2012; Petersen et al.,
2001; Ritchie et al., 2010; Van Heertum and Tikofsky, 2003). Critically,
studies have demonstrated that AD pathogenesis follows a temporally
rapid and predictable course with respect to the regional distribution
of Aβplaque deposition in thebrain (Braak and Braak, 1995). Thus, diag-
nostic strategies targeting Aβ plaques gain a key advantage over other
AD biomarkers in that our ability to detect subtle changes in Aβ deposi-
tion is the greatest in the regions that change early in the course of AD
pathogenesis. Unfortunately, once considerable plaque deposition has
occurred, treatments aimed at abolishing these protein aggregations
have limited efﬁcacy with respect to restoration of cognitive function,
largely as a consequence of the irreversible nature of neuronal damage.
Therefore, because neuronal damage cannot be ameliorated, early AD
diagnosis and prevention are of paramount importance in the manage-
ment of AD, as this treatment paradigm likely represents our best hope
of curtailing disease burden. Despite the discovery of potentially efﬁca-
cious therapeutic approaches, the clinical impact of AD treatments re-
mains underwhelming, due in part to a lack of reliable methodologies
by which to screen for AD pathology (Aisen and Vellas, 2013; Delrieu
et al., 2012; Lansbury, 2004; Merlini and Bellotti, 2003; Rosenberg,
2005).
Of the early diagnostic modalities proposed for AD, amyloid imaging
has emerged as the most promising approach with respect to developing
a noninvasive yet clinically relevant diagnostic methodology (Cummings
and Cotman, 1995; Cummings et al., 1996; de Souza et al., 2012; Perrin et
al., 2009; Risacher and Saykin, 2013;Weiner et al., 2012). Today, themost
cited modalities in the ﬁeld of amyloid imaging include optical, MRI and
PET-based approaches. For example, optical imaging has been used to
monitor the development of a single Aβ plaque and reveal subtle neurite
geometry changes that occur in and around diffuse plaques (D'Amore et
al., 2003). Similarly, while structural MRI provides exquisite anatomical
contrast due to its high spatial resolution, functional and volumetric
MRI have also been utilized to predict AD onset with nearly 80% accuracy
(Jack et al., 1999; Kerchner, 2011; Kofﬁe et al., 2011; Wang et al., 2006;
Yanagisawa et al., 2011). Nevertheless, despite the potential advantages
offered by MRI and other optical-based methodologies, PET/CT imaging
is still considered the most practical approach because of its sensitivity,
detection depth and the ability of PET probes to retain binding afﬁnity
for neuroimaging of Aβ plaques (Cohen et al., 2012; Ikonomovic et al.,
2012). Despite the real-world availability of PET/CT, amyloid imaging fa-
cilitated by this technique is currently limited by the scarcity of speciﬁc
molecular probes capable of binding to Aβ plaques. Today, the fewprobes
available for PET-based human amyloid imaging include 18F-BAY94-9172
(18F AV-1) (O'Keefe et al., 2009), 18FAV-45 also known as 18F-Florbetapir
(Choi et al., 2009), 18F-Florbetaben (Villemagne et al., 2011) and 11C-PIB
compounds (Klunk et al., 2004, 2007; Mathis et al., 2012; Mintun et al.,
2006). When 18F-Florbetapir was utilized in a well-controlled, random-
ized study estimating the accuracy of AD diagnosis with and without
the assistance of amyloid imaging, diagnostic conﬁdence increased by
approximately 21.6%, and 54.6% of clinically based diagnoses were
overturned (Grundman et al., 2013). Similarly, a meta-analysis of ran-
domized, controlled trials evaluating the diagnostic efﬁcacy of 11C-PIB es-
timated its sensitivity and speciﬁcity at 93.5% and 56.2%, respectively
(Zhang et al., 2012). To date, these compounds have been developed
using structural similarity approaches based on the chemical structure
of thioﬂavin or congo red ﬂuorescence dyes (Mathis et al., 2012). Howev-
er, this deductive approach restricts the ability to select a large number of
unorthodox compounds available from a screening library that may bind
not only to Aβ plaques, but also encompass other criteria such as the abil-
ity to cross the bloodbrain barrier (BBB). In general, the notable paucity of
Aβ binding probes results from the absence of a reliable, high-throughput
screening assay capable of identifying novel compounds that bind to Aβ
plaques.Here, we demonstrate a combinatorial approach which integrates a
newly designed, high-throughput amyloid thioﬂavin competitive binding
optical assay (HATCO) with matrix-assisted laser desorption/ionization
imagingmass spectrometry (MALDI IMS) to facilitate the screening of di-
verse compound libraries for molecules that possess the ability to bind to
Aβ plaques. The HATCO technique provides a robust means of improving
the chance for a hit in two distinct ways: ﬁrst by facilitating the rapid
screening of large compound libraries, and second by removing the in-
trinsic limitations associatedwith a thioﬂavin-analog-based probe design.
Subsequent utilization of MALDI IMS further expedites the probe design
process by obviating investments associated with radiolabeling potential
hits discovered in the high-throughput screening phase of our approach.
Furthermore, MALDI IMS provides complementary data unobtainable via
independent implementation of theHATCO assay by facilitating the direct
analysis of intact tissue and preserving the spatial distribution of mole-
cules within that tissue. Thus, MALDI IMS-based analysis of HATCO-
discovered hits enables researchers to assess the biological relevance of
the molecule's retention pattern in the brain via comparison with
known regions of Aβ plaque distribution (Seeley and Caprioli, 2008). To
demonstrate the utility of our combinatorial approach to amyloid probe
development, we identiﬁed promethazine as a potential agent for amy-
loid imaging among a small library of HATCO-screened compounds
(Fig. 1). Adding promethazine to amixture of freshly isolated andhomog-
enized 5XFADmouse brain and thioﬂavin resulted in a signiﬁcant attenu-
ation of the ﬂuorescence signal, which suggests the compound competes
with amyloid-binding thioﬂavin. Administration of promethazine via tail
vein injection into 5XFAD transgenic mice overexpressed with human
APP and PS1 resulted in a signiﬁcantly greater promethazine signal in
amyloid-burdened 5XFAD brains compared to wild-type (WT) mice as
detected by MALDI IMS. Lastly, the colocalization of promethazine signal
in the 5XFADmousemodel with the signal produced by the Aβ40 peptide
further suggests the interaction of promethazine with amyloid plaques.
2. Materials and methods
2.1. Reagents and mouse model
Thioﬂavin, naltrexone, and all other chemicals and solvents including
methanol, DMSO, andDMFwere obtained fromSigma-Aldrich at reagent
grade. All chemicals were used without further puriﬁcation. The absorp-
tion spectra were measured on a UV–Vis spectrophotometer (Agilent).
Fluorescent measurements were made using a QM-4SE spectroﬂuorom-
eter (Photon Technology International). The 5XFADmice were obtained
from Jackson Laboratory (Bar Harbor, ME). This APP/PS1 double trans-
genic mouse model was developed by Vassar et al. (Oakley et al., 2006).
2.2. Animals and brain perfusion
5XFAD and WT mice of different ages were obtained from the
in-house Vanderbilt breeding facility and housed in a temperature
controlled, 12-hour light/dark cycle facility. After injection of the test-
ed compounds (25 mg/kg), at a designated time point, including
10 min and 4 h, cardiac perfusion was performed. A sharp incision
into the abdomen of the anesthetized mouse was made. This was
followed by a longitudinal cut with a scalpel to open the thoracic cav-
ity, which then was stabilized with a retractor. Perfusion began with a
20-gauge syringe containing ice cold PBS (30 ml, pH 7.4) in the left
ventricle while the atrium was snipped followed by the injection of
paraformaldehyde (PFA) solution (4%). Once the perfusion was com-
pleted, the animals were decapitated and the brains were quickly re-
moved and ﬁxed in PFA overnight at 4 °C followed by sucrose
precipitation overnight at 4 °C. The brains were then embedded in
Cryo-OCT compound (Fisher Scientiﬁc) before sectioning. All animal
experiments performed complied with institutional guidelines and
were conducted according to the protocol approved by the Vanderbilt
Institutional Animal Care and Use Committee.
Fig. 1. Chemical structures and molecular weights of thioﬂavin and candidate amyloid-binding compounds. Thioﬂavin and a series of selected compounds comprising a small mo-
lecular library were screened for the ability to bind Aβ plaques using the HATCO assay. Structural diversity was maximized within this library to include benzimidazole,
benzylisoquinoline, butyrophenone, tetracycline and phenothiazine motifs contributed by astemizole, naltrexone, haloperidol, minocycline, and promethazine, respectively.
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Thioﬂavin stock solutions were prepared by dissolving 1.3 mg in
100 mL of dd. water. The solution was passed through a micro ﬁlter
after which the concentration was measured using Beer's law using an
extinction coefﬁcient of 26,620 M−1 cm−1 at 416 nm. The stock solu-
tion was stored in darkness using aluminum foil and kept at 4 °C during
the assay. Fresh stock solutionwas prepared for each assay. Fluorescence
was measured using excitation/emission parameters at 465/565 nm
with 5 nm slits, 0.1 second integration time and at 1-nm intervals
using a Photon International ﬂuorometer. In a typical measurement,
thioﬂavin (50 μL, 40 μM) was added to 100 μL of freshly prepared and
vortexed 5XFAD amyloid lysate (70 mg/mL). The mixture was incubat-
ed at room temperature for 10 min. After incubation, test compounds
(50 μL) in PBS (50 mM) were added to the mixture. The concentration
of the tested compounds was 250 μM. After equilibration for 10 min at
room temperature, the ﬂuorescence signal of the sample was measured
at an emission lambda max of 480 nm. All measurements were
performed in triplicate and data are presented as mean with standard
deviation.
2.4. Thioﬂavin ﬂuorescence staining
Cryostat prepared coronal midbrain slides (8–12 μm thickness)
were mounted and ﬁxed using PFA. The slides were stored at−80 °C
until use. Before staining, slides were thawed and placed in 4% PFA for
10 min before being transferred to TRIS buffer for 5 min and dried be-
fore exposure to the thioﬂavin solution (1% dye content). The stained
slides were maintained at 37 °C for 30 min after which the excess
thioﬂavin was removed prior to rinsing in the TRIS buffer for 1 min.
The slides were then dipped into 95% ethanol followed by 100% ethanol
for 6 s. They were then allowed to air dry at room temperature.Coverslips were added to slides using Vecta shield mounting solution
and allowed to dry overnight prior to ﬂuorescence microscopy using
DAPI ﬁlter channel.
2.5. Quantiﬁcation of the uptake by HPLC
Whole brains from perfused 5XFAD or WT mice treated previously
with promethazine at different times were collected, weighed, and ho-
mogenized in PBS (g tissue/3 mL PBS) using a homogenizer (Tissuemizer
Homogenizer, Fisher Scientiﬁc, Pittsburg, PA). The homogenized solution
was added with 20% acetonitrile and warmed at 70 °C using a heating
block for 10 min to maximize promethazine extraction. The extract was
lyophilized and then reconstituted with HPLC buffers. After establishing
the detection limit of the instrument and determining a promethazine
concentration–response calibration curve, the quantitative amount of
promethazine in the brain lysate against the injected dose was analyzed
by integrating the area under the curve using EZChrome Elite software
(Hitachi). Every retention time peak in the spectrum was collected and
analyzed using LC–MS.
2.6. Amyloid lysate preparation
Excised midbrains were homogenized for 5 min in 200 μL of buffer
comprised of 21.4 g sucrose, 5 mL of 1 M tris base, and 0.5 mL of
0.5 M EDTA/250 mL DPBS using the T-25 basic Ultra-Turrax homoge-
nizer. Additional 100 μL aliquots of this buffer were then added to the
homogenized sample and re-homogenized for 2 min until a total
added volume of 800 μL was attained. The sample was diluted to 4 mL
total volume using another buffer comprised of 5% BSA, and 0.03%
Tween 20 in DPBS solution. Roche Complete protease inhibitor tablets
were added to both buffers immediately prior to use (1 tablet/10 mL
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quots of the supernatant were stored at−80 °C until use.
2.7. MALDI IMS imaging
Analyse of promethazine were performed on an LTQ XL linear ion
trap mass spectrometer equipped with a MALDI source (ThermoFisher,
Waltham, MA). Fresh frozen mouse brain coronal sections of 12 μm
were thaw-mounted onto gold-coated, stainless steel target plates
which were kept at room temperature in a vacuum desiccator until
analysis. A serial section was obtained on a glass slide and stained
using hematoxylin and eosin. The tissue sections were manually coated
with matrix (DHB, 30 mg/mL in 50:50 methanol:water with 0.1%
triﬂuoroacetic acid) using a glass nebulizer (thin-layer chromatography
reagent sprayer, Kontes Glass Company, Vinland, NJ). The matrix was
applied by passing the sprayer across the tissue section several times
and allowing the tissue to dry. This processwas repeated approximately
20 times to ensure a homogeneous coating of matrix crystals formed on
the tissue section while minimizing analyte delocalization. After coat-
ing, the target plate was attached to a modiﬁed LTQ slide holder and
inserted into the instrument. MS/MS spectra for promethazinewere ac-
quired over the entire tissue section at 100 μm spatial resolution. An
isolationwindow (1.0 amu) centered onm/z 285was selected to isolate
the precursor ion for PMZ. This was subjected to collisionally activated
dissociation (CAD) at a collision energy of 27. Main fragment ions
were formed atm/z 86 and 198 (likely corresponding to fragmentation
at the phenothiazine-N) as well as at m/z 240 (likely corresponding to
loss of the dimethylamine moiety) (Niessen, 2011). Images representa-
tive of the distribution of PMZ across the tissue section were generated
by plotting the summed intensity of the main fragment ions at m/z 86
and 240 at each pixel using ImageQuest software (Thermo Scientiﬁc,
Waltham, MA). Analyses of amyloid peptides were performed on a
linear MALDI time-of-ﬂight mass spectrometer (Autoﬂex, Bruker
Daltonics, Billerica, MA). The samples on the plate analyzed using the
LTQ were washed in sequential steps of 70% ethanol, 100% ethanol,
Carnoy's solution (60% ethanol, 30% chloroform, 10% acetic acid), and
water to remove the matrix and potential ion suppressant's such as
lipids and salts. After reapplying the matrix, three brain sections were
imaged in positive ionmode fromm/z 2500–7000 at a spatial resolution
of 75 μm. Speciﬁc ion images were reconstructed in ﬂeximaging soft-
ware (Bruker Daltonics, Billerica, MA).
2.8. Image analysis
Each coronal brain slice was manually segmented to create indi-
vidual ROIs of the hippocampus and isocortex or of the whole coronal
section. The Allen mouse brain atlas was used as a reference for the
segmentation of these regions and analysis was performed by an out-
side collaborator. The ROIs were then used to isolate the pixels in the
MALDI ion images representing promethazine (m/z 86 + 240) and
the pixels within the direct Aβ40 images (m/z 4331+/−4). Once
the images were segmented, mean signal values were calculated
(Fig. 5B). Next, the pixels within each ROI were segmented into two
groups using the k-means clustering algorithm, which represents sig-
nal vs. no signal. The comparison of these measurements is shown in
Fig. 5C.
3. Results
3.1. HATCO assay-mediated screening for novel Aβ-binding compounds
Thioﬂavin is classiﬁed as a topologically activated dye that binds
speciﬁcally to Aβ plaques (Nolting et al., 2011). This class of compounds
possesses substantial conformational freedom while remaining in free
solution and thus exhibits a relatively lowﬂuorescence signal. However,
upon binding to Aβ plaques, thioﬂavin's conformational freedom isdramatically reduced. This increase in structural rigidity decreases the
vibrational–rotational processes available to the thioﬂavin molecule,
resulting in a decreased radiation decay rate of thioﬂavin in both ground
and excited states. Cumulatively, these phenomena contribute to the
observed increase in thioﬂavin's ﬂuorescence quantum yield when
bound to Aβ plaque compared to the unbound molecule (Nesterov et
al., 2005; Voropai et al., 2003). Although increased thioﬂavin ﬂuores-
cence alone is highly indicative of the thioﬂavin molecule existing in
anAβ-bound state, secondary validation of this fact is available as a con-
sequence of a characteristic spectral shift in thioﬂavin's ﬂuorescence
signal observed only when thioﬂavin is bound to Aβ plaques. As
discussed, when not complexed with Aβ, thioﬂavin emits a weak ﬂuo-
rescent signal at a λmax of 440–445 nm. However, when bound to Aβ
plaques, thioﬂavin's ﬂuorescence increases dramatically resulting in a
strong ﬂuorescent signal with a characteristically shifted λmax of ap-
proximately 480 nm (Hudson et al., 2009; LeVine, 1993).We employed
these unique characteristics of thioﬂavin to develop the HATCO assay
for screening compounds for the ability to bind to Aβ plaques in a
high-throughput fashion. In an effort to utilize the most biologically
representative Aβ plaques possible, fresh brain lysates were obtained
from 5XFAD mice and analyzed using the Bradford assay to ensure an
equal amount of protein was used in each assay trial. Before performing
a speciﬁc displacement study, we conducted a series of control experi-
ments intended to (i) assess whether the tested library of compounds
emitted or absorbed at wavelengths might confound thioﬂavin's signal
by overlapping with its excitation or emission spectra and (ii) demon-
strate the speciﬁcity of thioﬂavin toward Aβ plaques. As shown in
Fig. 2A,when the compoundsweremixedwith thioﬂavin in the absence
of Aβ plaque, no signiﬁcant modulation of thioﬂavin ﬂuorescence is ob-
served. These ﬁndings lend strong support to the claim that the com-
pounds tested do not bind to thioﬂavin directly and are incapable of
directly modulating its ﬂuorescence due to overlapping spectra. In sup-
port of thioﬂavin's afﬁnity for Aβ plaques, mixing thioﬂavin (10 μM)
with Aβ plaques (35 mg/mL) contained within the 5XFAD brain lysate
resulted in a nearly 19-fold enhancement in thioﬂavin ﬂuorescence sig-
nal compared to a control sample (P b 0.0001) in which the same con-
centration of thioﬂavin was dissolved in PBS without Aβ protein.
Importantly, the enhanced ﬂuorescence signal of thioﬂavin observed
in the presence of the 5XFAD lysate exhibited a λmax of 480 nm, a
characteristic of thioﬂavin bound to Aβ plaques. By comparison, the
thioﬂavin mixed with PBS controls emitted most strongly at 440 nm,
which is the λmax associated with unbound thioﬂavin. In a more rigor-
ous demonstration of thioﬂavin's speciﬁcity for 5XFAD-derived Aβ
plaques, we treated the same thioﬂavin concentration with brain lysate
isolated from WT mice lacking Aβ plaques. Despite some degree of
non-speciﬁc binding, a reliable differential in ﬂuorescence signal en-
hancement was observed between amyloid-containing 5XFAD lysate
and amyloid-deﬁcient WT lysate, which conﬁrmed our hypothesis
that thioﬂavin ﬂuorescence could be used as a reliable reporter to iden-
tify Aβ-binding compounds. Again, spectral analysis of thioﬂavin's ﬂuo-
rescence in the presence of WT lysate reveals a λmax of 440 nm as
compared to the λmax of 480 nm observed in the 5XFAD trials. This
spectral shift conﬁrms the thioﬂavin ﬂuorescence signal utilized as a re-
porter in the subsequent HATCO assays reliably reﬂects the proportion
of Aβ-bound thioﬂavin. Thus, any observed modulation in thioﬂavin
ﬂuorescence when the compounds are added cannot represent the dis-
sociation of thioﬂavin from non-Aβ proteins, as these complexes do not
contribute to the measured thioﬂavin signal at 480 nm (Fig. 2B).
Next, we tested the ability of the compounds to displace thioﬂavin
for binding to Aβ plaques. Again, the assumption was that if thioﬂavin
is dissociated from Aβ plaques by a competitively binding compound,
the ﬂuorescence signal of thioﬂavin would be reduced. 5XFAD brain
lysates of normalized concentration were treated with thioﬂavin in
quartz cuvettes and allowed to equilibrate for 30 min before the addi-
tion of the tested library compounds. After equilibration, the propor-
tion of thioﬂavin molecules bound to Aβ plaques in solution was
Fig. 2. HATCO assay-mediated, high-throughput screening of structurally diverse compound libraries for Aβ plaque-binding capacity. (A) Fluorescence signal of thioﬂavin in the
presence of freshly isolated 5XFAD brain lysate, PBS or candidate compounds. The results demonstrate a 19-fold increase in thioﬂavin ﬂuorescence in the presence of 5XFAD lysate
compared to PBS and compound library trials (P b 0.0001). Values represent normalized ﬂuorescence with respect to PBS trial ± S.D. (n = 3). (B) Enhancement of thioﬂavin ﬂuo-
rescence in the presence of 5XFAD lysate compared to WT lysate. The spectral shift in thioﬂavin's λmax toward 480 nm in the presence of 5XFAD lysate arises as a consequence of
thioﬂavin-amyloid complexes and validates the reliability and speciﬁcity of the thioﬂavin reporter. Note that the emission maximum of 440 nm in the WT trials excludes the pos-
sibility of the thioﬂavin signal enhancements representing non-speciﬁc binding of thioﬂavin to endogenous peptides of the brain. Protein concentrations in 5XFAD and WT lysates
were normalized throughout the assays. (C) Increased thioﬂavin ﬂuorescence secondary to the presence of amyloid-containing 5XFAD lysate is attenuated by the addition of
promethazine but not by other candidate compounds. Promethazine reduces thioﬂavin ﬂuorescence at 480 nm by 15.6% with respect to PBS trials (P b 0.0001). The results suggest
promethazine may displace thioﬂavin for amyloid plaques and thus attenuate the ﬂuorescence signal. All measurements were performed in triplicate at candidate compound con-
centrations of 250 μM.
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pounds, we found that only promethazine caused a notable reduction
(19%) of thioﬂavin's ﬂuorescence signal (P b 0.0001) (Fig. 2C). Of
note, it is improbable that this signal attenuation is attributable to
ﬂuorescence resonance energy transfer (FRET), as promethazine is
not a chromophore and is therefore unable to interfere with the exci-
tation states of thioﬂavin via the FRET mechanism.
3.2. Blood brain barrier penetration
The next phase of experiments evaluated promethazine's ability
to cross the BBB and be retained in the brain parenchyma in an
amyloid-dependent manner. Wild-type and 5XFAD mice (n = 3 per
group) were injected with promethazine (25 mg/kg) via the tail veins
and subsequently perfused 10 min or 4 h post-injection. Freshly isolat-
ed brains were then homogenized to facilitate extraction and quantiﬁ-
cation of the promethazine contained within the sample via HPLC
using a procedure reported by our group previously (Kumagai et al.,
2012). As shown in Fig. 3, following a brief systemic distribution, we
noted pronounced peaks at retention times of 15 and 17 min, which
corresponded to (R) and (S) enantiomers, respectively (Allender and
Archer, 1984; Ponder and Stewart, 1995). Of note, themolecularweight
of the molecule associated with the peaks at 15 and 17 min match that
of promethazine as determined by LC–MS and identically matches the
peaks obtained by HPLC analysis of a racemic promethazine solution
(data not shown). Among the WT mice, the peaks corresponding
to both (R)- and (S)-promethazine disappeared 4 h post-injection.
However, both enantiomers of promethazine remained in amyloid-
burdened 5XFAD brains 4 h post-injection. Interestingly, retention of
the (S)-enantiomer appeared favorable compared to that of the (R) con-
ﬁguration. This may suggest that the (S) conﬁguration of promethazine
is principally responsible for binding to Aβ plaques. Using standardized
concentration curves and integration software available from the HPLC
system, we calculated that 2% and 0.5% of the original promethazine
dose was retained 10 min post-injection in 5XFAD and WT mice, re-
spectively. Thus, promethazine exhibits a 4-fold higher retention in
amyloid-burdened brains at the 10-minute time-point with respect to
WT controls. At the 240-minute time-point, 0.5% of the original dose
remained in 5XFAD brains compared to 0.01% retention in the WT ani-
mals. These results represent a signiﬁcant difference in the retention of
promethazine as a function of Aβ plaque burden in the brains at the
240-minute time-point. Further analysis of this data reveals that
the amount of promethazine retained in the brain of WT mice drops
97% during the 10- to 240-minute time interval, while promethazineretention falls by only 75% in amyloid-burdened 5XFAD brains. We
performed a control study to demonstrate the notion that compounds
lacking any kind of binding targets in the brain will be virtually 100%
cleared an hour after administration. Toward that goal, we injected
Cy5.5 succinimide ester dye (2 nmol) into the left ventricle of a
mouse and tracked the distribution using an optical imaging system.
Immediately after injection, we observed the dye diffused into the
brain tissues; however, one hour post-injection, no trace of thematerial
was detected in the brain (Supplementary data, Fig. S1). Thus, the ﬁnd-
ing that the rate of promethazine clearance in the brain varies in an
amyloid-dependent manner is best explained by the ability of the com-
pound to bind to Aβ plaques. Taken together, the data conﬁrm that
promethazine can penetrate the BBB and be retained in the brain in
an amyloid-dependent manner.
3.3. MALDI IMS ex vivo imaging of promethazine's spatial distribution in
the 5XFAD brains
Before analyzing the distribution of promethazine in the brains of
treated mice, we optimized the MALDI IMS method for promethazine.
Promethazine was analyzed on a linear ion trap equipped with a
MALDI source (Thermo LTQ XL), using 2,5-dihydroxybenzoic acid
(DHB) as the matrix. Promethazine forms a protonated ion at m/z
285.1, which was subjected to collisionally activated dissociation.
Fragmentation occurs at the nitrogen moieties, resulting in three
main fragment ions including the phenothiazine ring, a substituted
N-propyl phenothiazine, and N,N-dimethylisopropylamine at m/z
198, 240 and 86, respectively. These ions are unique to promethazine
and are not observed in the DHB matrix (Fig. 4A & B).
Next, we determined whether promethazine accumulates sufﬁ-
ciently in the brain to permit detection. Eight-month-old 5XFAD
(n = 5) and age-matched WT mice (n = 3) were used to assess the
distribution and localization of promethazine in the brain. The animals
were injected with promethazine (25 mg/kg) via the tail vein followed
by brain perfusion 4 h post-injection. Non-dosed animals were used as
controls. After perfusion, the brains were removed and ﬂash frozen. The
frozen brains were then sectioned into 12-μm thick slices, coated with
DHB, and analyzed on the LTQ via pseudo-selected reaction monitoring
(SRM). Fig. 4C shows the detected promethazine signal (from m/z 86)
on representative brain sections from dosed WT (top), non-dosed
5XFAD (middle), and dosed 5XFAD (bottom) animals. As shown, there
is no measurable signal from the non-dosed sample. Promethazine is
detected fromboth dosed animals, but there is a signiﬁcantly higher sig-
nal from the 5XFAD sections. Similar imageswere obtained for the other
Fig. 3. HPLC determination of BBB penetration and differential retention of (S)-promethazine in 5XFADmouse model. Ten minutes post-injection, detectable levels of promethazine
were measured in both WT (mean = 2.57 μg) and 5XFAD (mean = 9.62 μg) mouse models, thus conﬁrming promethazine's ability to cross the BBB in both models. At this
time-point, 0.5% of the original promethazine dose is retained within the brains of WT mice compared to 2% retention in the 5XFAD model. This is approximately a 4-fold increase
in promethazine retention in amyloid-burdened brains. At the 240-minute time-point 0.5% of the original dose retained in 5XFAD brains versus 0.01% in WT mice. Given that the
difference in promethazine retention betweenWT and 5XFAD grows over time, it is highly probably the enhanced retention of promethazine in amyloid-burdened brains reﬂects an
afﬁnity of promethazine for Aβ plaques. Tail vein injection of racemic mixtures of promethazine facilitated the determination of stereo-speciﬁc binding. Note that both the (R)- and
(S)-promethazine enantiomers are retained at relatively the same level in WT brains; however, the (S)-version is retained at higher levels 240 min post-injection in the 5XFAD
mice. These results support the conclusion that the (S)-promethazine enantiomer may be primarily responsible for Aβ plaque binding. Further, cardiac perfusion protocol was
performed prior to brain extraction/homogenization to avoid confounds associated with promethazine being retained in the micro-vasculature. All measurements were performed
in triplicate with each dose equivalent to 25 mg/kg.
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speciﬁcity of the analysis.
3.4. Corroboration of promethazine's regional retention with Aβ plaque
distribution in the brain using MALDI IMS
In this phase of the study, coronal brain sections from three groups
of mice were used to investigate whether the regional distribution ofFig. 4. Validation of promethazine imaging using MALDI IMS. (A) Chemical structure of prom
Fragmentation of promethazine generates ions with unique m/z values (red circles) that ar
coronal brain slices of dosed 5XFAD and WT mice at three ions. Mice were given a cumulati
Animals were subsequently sacriﬁced 3 h following the last injection. Note the enhanced re
The high degree of corroboration between all three m/z peaks conﬁrms the speciﬁcity of thpromethazine mirrored that of Aβ plaques. Two-month-old (n = 4)
and 8-month-old 5XFAD (n = 4) mice as well as 8-month-old WT
mice (n = 4) were dosed with 25 mg/kg of promethazine via tail
vein injections. Cardiac perfusion was subsequently performed 4 h
after treatment, and the brains were freshly frozen and prepared for
MALDI IMS analysis. By employing the MALDI IMS methodology, we
were able to determine the regional distribution and relative abun-
dance of promethazine and the Aβ40 peptide within a single coronalethazine and its fragmentation pattern under the described MALDI IMS condition. (B)
e distinct from the DHB matrix. (C) Visualization of promethazine retention in 12-μm
ve dose of 25 mg/kg of promethazine using four tail vein injections at 2-hour intervals.
tention of promethazine in amyloid-burdened brain tissue (5XFAD) compared to WT.
is protocol for promethazine (n = 3 per group).
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research as a major constituent of mature Aβ plaques, and it has been
shown to possess considerable cytotoxicity (Ghiso and Frangione,
2002; Masters et al., 1985b). Thus, our study assumes that Aβ40 deposi-
tion reasonably reﬂects the regional Aβ plaque load in any given region
of the brain. As illustrated in Fig. 5A, direct imaging of the Aβ40 peptide
reveals a 5-fold increase in Aβ plaque burden in the 8-month-old 5XFAD
cohort as compared to both the 2-month-old 5XFAD animals and
age-matchedWT controls. Furthermore, critical analysis of these images
further reveals a predilection for Aβplaque deposition in speciﬁc regions
of the brain including the isocortex and hippocampal CA1–CA3 areas. In-
terestingly, both the promethazine and Aβ40-generated signals mea-
sured in the 2-month-old 5XFAD mouse cohort did not differ
signiﬁcantly from those of treated WT brains. This ﬁnding is consistent
with thioﬂavin staining,which conﬁrms thatAβ plaques are notwell de-
veloped at this age (Supplementary data, Fig. S2). In an effort to demon-
strate promethazine's potential efﬁcacy as a reporter of Aβ plaque
burden in the brain, we ﬁrst quantiﬁed the total promethazine-
generated MALDI IMS signal in each of the three cohorts. To do this,
we employed standard image processing techniques which rely on
transformation of the MALDI IMS data into a binary image format to fa-
cilitate quantiﬁcation of the average signal intensity generated by
promethazine and the Aβ40 peptide. As depicted in Fig. 5B, MALDI IMS
imaging of promethazine in 8-month-old 5XFAD animals revealed a sig-
nal intensity nearly 3-fold greater than that of age-matchedWT animals.
In contrast, promethazine-dosed WT mouse brains exhibit virtually no
Aβ40-generated signal and aminimal signal representing promethazine.
This data is consistent with the HPLC data presented in Fig. 3, which in-
dicates that only residual amounts of promethazine remain in the brain
of WT mice 240 min post-injection. Notably, the signal trends observedFig. 5. Differential retention of promethazine as a function of Aβ plaque burden. (A) Repres
(4 h post injection) were assembled on a gold plate for analysis via MALDI IMS. In the Aβ4
cohorts implies that Aβ plaques are not well developed in 2-month-old 5XFADmice. Importa
between 5XFAD and WT models as alternative explanations of the differential retention of P
between 2- and 8-month-old 5XFAD mice conﬁrms promethazine's potential to serve as a p
(B) Quantiﬁcation of total brain promethazine and Aβ40-generated MALDI IMS signal in WT
promethazine-generated MALDI IMS signal above background levels. The mean promethazin
greater than that of WT controls (n = 3, P b 0.01). Furthermore, no signiﬁcant differences in
WT controls (P = 0.47). Critically, these trends in promethazine retention between experim
thus supporting the conclusion that promethazine retention in the brain is amyloid depend
relevant regions of interest. Overlay of MALDI IMS promethazine images with the Allen mou
signal intensities within the hippocampus and isocortex. Mean signal values from these regio
promethazine retention was signiﬁcantly greater in 8-month-old 5XFAD mice compared to W
erentially in amyloid-burdened brains in regions of the brain known to be susceptible to Ain promethazine signalmirror those of direct Aβpeptide imaging; as sig-
nal intensities derived from both promethazine and the Aβ40 peptide are
similarly elevated in 8-month-old 5XFADmice compared to age-matched
WTcontrols. In addition, the level of Aβplaqueburden assessed byMALDI
IMS imaging of the Aβ40 peptide is comparable within experimental
groups, a ﬁndingwhich alludes to the possibility of inter-subject compar-
isons of Aβ plaque burden using this technique. Lastly, no promethazine-
generated signal was detected in non-promethazine-dosed 8-month-old
5XFAD brains (n = 2, Supplementary data, Fig. S3), thus excluding the
possibility of signal artifacts underlying the observed differences in
promethazine retention. However, it remained possible that the
brain regions responsible for generating the enhanced promethazine
signal in the 8-month-old 5XFAD cohort might not be of biological
signiﬁcance with respect to AD pathophysiology. Therefore, we sought
to investigate whether regions of known pathological signiﬁcance, in-
cluding the isocortex and hippocampal ﬁelds possessed promethazine
signal differences like those observed in the whole brain analysis. As
depicted in Fig. 5C, quantiﬁcation of the MALDI IMS signal intensities
generated by promethazine within each experimental group supports
the conclusion that promethazine is retained as a function of the Aβ
plaque burden in regions of the brain relevant to AD pathophysiology.
On average, the promethazine signal measured in the brains of
8-month-old 5XFAD mice is 2-fold greater than that of age-matched
controls in both the hippocampus and isocortex (n = 3 per region,
P b 0.01). In congruence with our whole brain analysis, no signiﬁcant
differences in promethazine retention were observed between WT and
2-month-old 5XFAD animals in either of these regions. Considered to-
gether, the similarity in mean signal values generated by promethazine
and Aβ40 in each experimental cohort, in addition to the evidence
which illustrates that these trends are observable in biologically relevantentative coronal brain slices obtained from promethazine-treated WT and 5XFAD mice
0 imaging panel, the comparable signal intensities in the WT and 2-month-old 5XFAD
ntly, this ﬁnding excludes differences in BBB permeability or brain protein composition
MZ observed in the 8-month-old 5XFAD group. The differential signal intensity of PMZ
roxy of Aβ plaque burden as well as demonstrates its speciﬁcity for mature Aβ plaques.
and 5XFAD mice. Signal intensity was calculated as the percentage of pixels exhibiting
e-generated MALDI signal obtained from brains of 8-month-old 5XFADmice was 3-fold
promethazine-generated signal were observed between 2-month-old 5XFAD mice and
ental cohorts directly mirror those observed via direct visualization of the Aβ40 peptide,
ent. (C) Quantiﬁcation of promethazine-generated MALDI IMS signal in pathologically
se brain reference atlas facilitated quantiﬁcation of the mean promethazine-generated
ns were then normalized to age-matchedWT controls. Within these regions of interest,
T controls (n = 3, P = 0.006). The results suggest that promethazine is retained pref-
β plaque aggregation.
627R.A. McClure et al. / NeuroImage: Clinical 2 (2013) 620–629brain regions, lends convincing support to the conclusion that
promethazine is preferentially retained in the brain in an amyloid-
dependent manner.
3.5. MALDI IMS for amyloid peptides
The same sections analyzed for promethazine were analyzed for in-
dividual amyloid peptides. The sample plate was put into a time-
of-ﬂight MS (Bruker Autoﬂex TOF) and analyzed in linear positive ion
mode fromm/z 2500–7000. A number of signals corresponding to am-
yloid peptideswere detected, as shown in Table 1 (based onhuman am-
yloid precursor protein, Swiss Prot entry number P05067). The signal
for m/z 4332, corresponding to Aβ (1–40) was the most abundant Aβ
signal. The localization of m/z 4332 is shown in Fig. 5. As shown, the
8-month-old 5XFAD brains show the highest amount of amyloid pep-
tide signal. The resulting image is similar for all amyloid ions detected
(data not shown). It is interesting to note that the amount of peptide
in the 2-month-old 5XFAD mouse is similar to the 8-month-old WT
mouse, supporting the observation from promethazine localization
that there is a reduced amount of plaques in the 2-month-old animal.
The high amount of Aβ peptide in the 8-month-old 5XFAD mouse
brain is consistent with the AD phenotype, and supports the notion
that promethazine is accumulating in the brain in the presence of amy-
loid plaques.
3.6. Statistical analysis
The experimental data were reported as mean ± SD. We com-
pared the test groups using the Mann–Whitney t-test using GraphPad
software (La Jolla, CA). P values are two-tailed and differences with P
values b0.05 were considered statistically signiﬁcant.
4. Discussion
Despite the availability of amyloid-binding contrast agents in clinical
trials, the development of novel probes remains a signiﬁcant bottleneck
in the overall effort to detect and treat AD. Given the costly develop-
ment and structural limitations intrinsic to thioﬂavin analog-based
probe design, the impetus for our work is the passion to ﬁnd new ap-
proaches which facilitate the identiﬁcation of unorthodox, amyloid-
binding compounds that can expand and potentially improve upon
our current repertoire of amyloid imaging agents. Although current am-
yloid imaging probes represent a considerable breakthrough in AD
research, complete validation of the diagnostic efﬁcacy of these com-
pounds will likely require decades of validation. In this work, we de-
scribe a robust, reliable and rational technique for the identiﬁcation of
ideal amyloid-binding compounds. This approach obviates the develop-
ment of unsuitable compounds and minimizes potentially colossal and
wasteful investment associatedwith traditional probe design strategies.
Yet another advantage of this technique is that both the HATCO assay
and MALDI IMS are suitable for the high-throughput platform. As
demonstrated in this work, the correlation between the candidate
compound's topographical brain distribution and that belonging to am-
yloid peptides can be used to lend biologically relevant support to a
compound's ability to serve as a proxy for Aβ plaque burden.
Among the library of compounds tested, promethazine alone atten-
uated the thioﬂavin ﬂuorescence signal in the presence of freshlyTable 1
MALDI IMS signals corresponding to Aβ40 in the brains of 5XFAD mice.
Peptide [M + H]+average, predicted [M + H]+, observed
Aβ 1–37 4075.5 4076
Aβ 1–38 4132.6 4134
Aβ 1–39 4231.7 4232
Aβ 1–40 4330.9 4332isolated 5XFAD brain lysates. This robust inhibitory proﬁle indicates
the possibility of direct displacement of thioﬂavin by promethazine
upon binding to Aβ plaques. This notion is supported by the fact that
thioﬂavin signal enhancement is due to binding Aβ plaques. In support
of this conclusion, we have demonstrated that the excitation/emission
spectra of thioﬂavin are not inﬂuenced by promethazine. To exclude na-
tive brain proteins as sources of the elevated thioﬂavin ﬂuorescence
used as a reporter in these experiments, we demonstrated that the
thioﬂavin signal is not enhanced when exposed to WT mouse brain ly-
sates. Having successfully identiﬁed a lead compound for our study, the
next task in our approach was to determine whether promethazine
could penetrate the BBB. This is an important step in our overarching ef-
fort to develop probes suitable for in vivo imaging, as many molecules,
including thioﬂavin are incapable of crossing that barrier. By using a ra-
cemic mixture of promethazine for in vivo injection, we demonstrated
that promethazine accumulates and is retained brieﬂy in normal brains
before being almost completely washed out after 240 min. However,
if brains were burdened with a signiﬁcant Aβ plaque density, the
(S)-promethazine is preferentially retained.
Ideal amyloid imaging probes that aim to dramatically impact AD re-
search should demonstrate the potential to detect Aβ plaque expression
well beyond the yes/no strategy. Rather, they should move toward the
capability of quantitatively evaluating plaque burden in order to facili-
tate intra-subject longitudinal studies of Aβ plaque load. As Aβ plaque
deposition is the hallmark of AD, such an ideal probe would become a
tool with which to assess plaque expression levels in response to ther-
apy and provide insight into the observed variability during the course
of the disease. Toward that end, 5XFAD and age-matched controls were
used for ex vivo MALDI IMS analysis of promethazine retention in the
brains. MALDI IMS imaging showed a clearly distinct signal difference
between promethazine-treated WT and 5XFAD mice after intravenous
injection of the compound. Impressively, the inter-sample consistency
of the promethazine-generatedMALDI IMS signal facilitates 100% accu-
rate discrimination of AD from WT mouse models using only a simple
threshold analysis. Given the convergent evidence offered by MALDI
IMS and corroborating HPLC data, we conclude that promethazine is
retained in an amyloid-dependent manner in the brain. Moreover, re-
gional differences in the retention of promethazine correlate well with
the spatial distribution of Aβ plaques in the brain which further sup-
ports the conclusion that promethazine is capable of binding Aβ
plaques. Overall, these ﬁndings support the speciﬁcity of promethazine
for Aβ plaques and its potential utility in assessingADplaque pathology.
Increasing the plausibility of this conclusion, although identiﬁed as part
of a random screening process, promethazine contains a unique struc-
tural scaffold which bears a striking resemblance to that of prototypical
amyloid-binding compounds. For instance, while thioﬂavin exhibits a
thiazole backbone, promethazine is supported by a phenothiazine
structural motif. While the two backbone structures are different, they
share common features including an N-alkylation extension from the
ring system and a dimethyl amine moiety. However, critical structural
differences between these compounds exist, which likely underlie
promethazine's ability to cross the BBB. For example, the electronic neu-
trality of promethazine probably facilitates its penetrance into the CNS,
while thioﬂavin's quaternary amine moiety imparts a positive charge
which reduces its lipophilicity and thus negatively impacts its bio-
distribution into the brain (Engkvist et al., 2003). Although indepen-
dently conﬁrmed in our work, we are keenly aware of promethazine's
bio-distribution proﬁle associated with its use as an antihistamine
drug. Despite being aware of the well-established side-effect proﬁle of
promethazine and other ﬁrst-generation antihistamines, a unique
aspect of PET imaging probe development is that this technique uses a
trace amount of radiolabeled compound, which is well below the
threshold for inducing adverse pharmacological effects. Fortunately,
the chemical structure of promethazine is quite unique relative to the
development of a [11C]carbon PET imaging probe via N-methylation
using [11C]methyl triﬂate or [11C]methyl iodide (Nolting et al., 2012).
628 R.A. McClure et al. / NeuroImage: Clinical 2 (2013) 620–629The advantage of this chemistry is that it retains the original chemical
structure of the labeled compounds, thusminimizing the risk of binding
afﬁnity alterations or biodistribution at the target site. As stated, howev-
er, a number of caveats still await resolution. At present, for instance, we
do not know the threshold at which we can distinguish the amyloid
binding signal from the signal emitted upon binding to histamine recep-
tors. Further, the binding afﬁnity of promethazine to Aβ plaque is large-
ly unknown, and that parameter is crucial to deﬁning a PET probe.
Notably, work is underway in our laboratory to address these issues.
5. Conclusions
We demonstrated a novel screening approach that facilitates the
identiﬁcation of amyloid-binding compounds and offers the potential
for adaptation to a high-throughput platform. This approach differs
from conventional probe discovery methodologies by extending be-
yond the in vitro binding afﬁnity assay and offering information regard-
ing a candidate probes performance in an in vivo model of AD. To
facilitate this improvement, we utilize the 5XFAD model, combined
with a robust mass spectrometry imaging capability. The MALDI IMS
method combines the multichannel (m/z) measurement capability of
mass spectrometry with a surface sampling process, enabling us to
probe and map the presence of promethazine in the brain tissues
(Cornett et al., 2007). In light of the substantial number of untested
and orphaned compounds untested with respect to Aβ plaque afﬁnity,
we anticipate that this combinatorial approach to probe development
will enhance the likelihood of getting a hit by facilitating rapid evalua-
tion of untappedmolecular libraries. Because of the operational simplic-
ity, high sensitivity, compatibility with high-throughput platforms, it is
our hope that the approach outlined in this work will serve to catalyze
far-reaching advances in the development and understanding of AD
pathophysiology, diagnostics and therapeutics.
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